Christian S. Schade

Aug 05, 2019

Aprea Therapeutics Appoints Scott Coiante as Chief Financial Officer

Apr 16, 2019

Aprea Therapeutics Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS)

Mar 25, 2019

Aprea Therapeutics Appoints Dr. Eyal C. Attar as Chief Medical Officer

Feb 27, 2019

Aprea Therapeutics Adds New Investor to Series C Financing

Nov 30, 2018

Aprea Therapeutics Closes EUR 50 Million Financing

Jan 04, 2018

Aprea Therapeutics Announces Presentation at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco

Aug 02, 2017

Aprea Therapeutics Announces First Patient Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Platinum-Resistant High-Grade Serous Ovarian Cancer